I. Aldoss

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.

G. Marcucci, I. Aldoss, S. Forman, 2021, Transplantation and cellular therapy.

Have any strategies in Ph-like ALL been shown to be effective?

I. Aldoss, A. Advani, Ibrahim Aldoss, 2021, Best practice & research. Clinical haematology.

Will immunotherapy lead to a breakthrough in the treatment of older adults with ALL?

I. Aldoss, A. Advani, V. Pullarkat, 2021, Best practice & research. Clinical haematology.

How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy

I. Aldoss, S. Forman, 2020 .

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

D. Weisenburger, G. Marcucci, I. Aldoss, 2019, Clinical lymphoma, myeloma & leukemia.

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.

C. Bloomfield, Cheng Cheng, J. Radich, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The identification and management of hereditary diffuse gastric cancer in a large Jordanian family

H. Lynch, I. Aldoss, J. Lynch, 2011, Familial Cancer.

Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia.

S. Rutella, J. Dipersio, P. Chevallier, 2020, Blood.

Effect of palliative care services on the aggressiveness of end-of-life care in the Veteran's Affairs cancer population.

I. Aldoss, T. Tashi, A. Ganti, 2011, Journal of palliative medicine.

The emerging story of acute lymphoblastic leukemia among the Latin American population - biological and clinical implications.

G. Marcucci, I. Aldoss, D. Douer, 2019, Blood reviews.

Immunophenotype of acute lymphoblastic leukemia in minorities‐ analysis from the SEER database

G. Marcucci, I. Aldoss, R. Nelson, 2021, Hematological oncology.

Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy.

I. Aldoss, P. Curtin, S. Forman, 2020, Blood advances.

Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1

I. Aldoss, V. Pullarkat, 2019, Leukemia & lymphoma.

Toxicity profile of repeated doses of PEG‐asparaginase incorporated into a pediatric‐type regimen for adult acute lymphoblastic leukemia

I. Aldoss, D. Douer, V. Pullarkat, 2016, European journal of haematology.

Donor derived leukemia in allogeneic transplantation

G. Marcucci, I. Aldoss, S. Forman, 2021, Leukemia and Lymphoma.

CD19/BAFF-R dual targeted CAR T cells for treatment of mixed antigen-negative variants of acute lymphoblastic leukemia

Xiuli Wang, L. Kwak, I. Aldoss, 2021, Leukemia.

The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.

G. Marcucci, I. Aldoss, S. Forman, 2019, Leukemia research.

Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myeloid leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Lixin Yang, G. Marcucci, I. Aldoss, 2019, Blood advances.

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity

I. Aldoss, J. Zaia, S. Forman, 2022, Blood Advances.

I. Aldoss, V. Pullarkat, 2012, Leukemia research.

Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab.

A. Nademanee, L. Kwak, I. Aldoss, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated with venetoclax.

A. Goldberg, G. Marcucci, I. Aldoss, 2022, Leukemia research.

Allogeneic hematopoietic cell transplantation in non-Hodgkin's lymphomas.

A. Nademanee, I. Aldoss, 2015, Cancer treatment and research.

Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

G. Marcucci, I. Aldoss, S. Forman, 2019, Bone Marrow Transplantation.

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2018, Haematologica.

Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse‐free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia

I. Aldoss, D. Douer, M. Akhtari, 2019, Cancer medicine.

Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use

G. Marcucci, I. Aldoss, V. Pullarkat, 2018, American journal of hematology.

Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital.

I. Aldoss, V. Pullarkat, Tamer Othman, 2020, Clinical lymphoma, myeloma & leukemia.

Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.

M. Tallman, I. Aldoss, M. Lunning, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An effective reinduction regimen for first relapse of adult acute lymphoblastic leukemia

I. Aldoss, A. Levine, D. Douer, 2013, Medical Oncology.

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemia

G. Marcucci, I. Aldoss, S. Forman, 2019, British journal of haematology.

Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia

G. Marcucci, I. Aldoss, S. Forman, 2021, British journal of haematology.

Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351)

G. Marcucci, I. Aldoss, S. Forman, 2021, American journal of hematology.

Venetoclax-containing regimens in acute myeloid leukemia

I. Aldoss, V. Pullarkat, A. Stein, 2021, Therapeutic advances in hematology.

Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents

G. Marcucci, I. Aldoss, S. Forman, 2021, American journal of hematology.

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

G. Marcucci, I. Aldoss, S. Forman, 2019, Blood advances.

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, P. Curtin, 2021, Cancer.

SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia

B. Wood, C. Willman, W. Stock, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

I. Aldoss, S. Forman, D. Snyder, 2022 .

Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.

I. Aldoss, S. Forman, V. Pullarkat, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Indications for allogeneic hematopoietic cell transplantation for adults with Philadelphia-chromosome negative acute lymphoblastic leukemia in first complete remission: all about MRD?

I. Aldoss, V. Pullarkat, 2018, Bone Marrow Transplantation.

FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell Transplantation

I. Aldoss, B. Ball, A. Blackmon, 2022, Blood and lymphatic cancer : targets and therapy.

Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2020, American journal of hematology.

I. Aldoss, D. Douer, V. Pullarkat, 2019, Blood reviews.

Acute Lymphoblastic Leukemia in the Older Adult.

I. Aldoss, S. Forman, V. Pullarkat, 2019, Journal of oncology practice.

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

J. Wong, G. Marcucci, I. Aldoss, 2022, Blood advances.

Nodular Regenerative Hyperplasia Causing Portal Hypertension in a Patient with Chronic Graft versus Host Disease: Response to Sirolimus

I. Aldoss, V. Pullarkat, L. Petrovic, 2014, Acta Haematologica.

Cetuximab in hemodialysis: A case report

I. Aldoss, A. Ganti, D. Lydiatt, 2009, Head & neck.

Prognostic and therapeutic implications of early treatment response assessment in acute myeloid leukemia.

I. Aldoss, V. Pullarkat, Ibrahim Aldoss, 2015, Critical reviews in oncology/hematology.

Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2019, Bone Marrow Transplantation.

Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors

A. Goldberg, G. Marcucci, I. Aldoss, 2022, Leukemia & lymphoma.

Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).

G. Marcucci, I. Aldoss, P. Curtin, 2022, Leukemia & lymphoma.

Total Marrow and Lymphoid Irradiation with Post-Transplant Cyclophosphamide for Patients with AML in Remission.

J. Wong, E. Radany, G. Marcucci, 2022, Transplantation and cellular therapy.

Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation

Jeffery Y C Wong, G. Marcucci, I. Aldoss, 2021, Leukemia & lymphoma.

Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable‐risk acute myeloid leukemia

G. Marcucci, I. Aldoss, A. Fathi, 2020, American journal of hematology.

Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy

G. Marcucci, I. Aldoss, S. Forman, 2020, Leukemia & lymphoma.

The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement

G. Marcucci, I. Aldoss, S. Forman, 2020, Leukemia & lymphoma.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

G. Marcucci, I. Aldoss, S. Forman, 2019, American journal of hematology.

Levocarnitine for pegasparaginase-induced hepatotoxicity in acute lymphoblastic leukemia

I. Aldoss, A. Salhotra, V. Pullarkat, 2020, Leukemia & lymphoma.

T. Slavin, G. Marcucci, I. Aldoss, 2018, Haematologica.

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

G. Marcucci, I. Aldoss, P. Curtin, 2022, Blood advances.

How I Treat the Toxicities of Pegasparaginase in Adults with Acute Lymphoblastic Leukemia.

I. Aldoss, D. Douer, Ibrahim Aldoss, 2020, Blood.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

B. Sandmaier, M. Horowitz, R. Gale, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

M. Slovak, G. Marcucci, I. Aldoss, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, V. Pullarkat, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

G. Marcucci, I. Aldoss, S. Forman, 2021, Bone Marrow Transplantation.

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

M. Krem, C. Hourigan, M. Aljurf, 2021, Blood advances.

Recurrent acute thrombocytopenia in the hospitalized patient: Sepsis, DIC, HIT, or antibiotic‐induced thrombocytopenia

J. George, B. Cowley, I. Aldoss, 2009, American journal of hematology.

Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, S. Forman, 2017, American journal of hematology.

Asparaginase: How to Better Manage Toxicities in Adults

I. Aldoss, D. Douer, V. Pullarkat, 2022, Current Oncology Reports.

SOHO State of the Art Updates and Next Questions | Asparaginase-Understanding and Overcoming Toxicities in Adults with ALL.

I. Aldoss, D. Douer, H. Pourhassan, 2022, Clinical lymphoma, myeloma & leukemia.

Asparaginase: Understanding and Overcoming Toxicities

I. Aldoss, D. Douer, 2021 .

Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia

I. Aldoss, V. Pullarkat, N. Tsai, 2018, Leukemia & lymphoma.

Adult Burkitt lymphoma: advances in diagnosis and treatment.

W. Chan, D. Weisenburger, J. Armitage, 2008, Oncology.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

R. Vij, B. Sandmaier, M. Aljurf, 2019, Haematologica.

Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia

F. Pichiorri, L. Ghoda, G. Marcucci, 2019, Leukemia.

The Bcl‐2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML

F. Pichiorri, L. Ghoda, G. Marcucci, 2019, Journal of cellular physiology.

Tumor intrinsic and extrinsic determinants of response to blinatumomab in adults with B-ALL.

Chunxu Qu, Jeremy R. Wang, C. Mullighan, 2020, Blood.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Guido Marcucci, Marco Marra, Zhaohui Gu, 2016, Nature Communications.

Clinicopathologic factors associated with lymph node retrieval in resectable colon cancer: A veterans' affairs central cancer registry (VACCR) database analysis

I. Aldoss, T. Tashi, A. Ganti, 2011, Journal of surgical oncology.

Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia.

An Liu, T. Schultheiss, J. Wong, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones.

I. Aldoss, S. Forman, D. Snyder, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML

G. Borthakur, M. Motwani, R. Gandour-Edwards, 2022, In Vivo.

Targeted therapy for squamous cell carcinoma of the head and neck.

I. Aldoss, A. Ganti, 2009, Journal of the Egyptian National Cancer Institute.

Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)

J. Dipersio, I. Aldoss, M. Arellano, 2021, Blood.

Cytokine gene polymorphisms are associated with response to blinatumomab in B‐cell acute lymphoblastic leukemia

Xiwei Wu, G. Marcucci, Wei Chen, 2021, European journal of haematology.

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma

A. Krishnan, M. Capelletti, I. Ghobrial, 2018, Leukemia.

MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

I. Aldoss, J. Zaia, J. Longmate, 2017, Blood.

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients

A. Nademanee, I. Aldoss, S. Forman, 2020, Annals of Internal Medicine.

Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemia

A. Logan, E. Jabbour, W. Stock, 2023, American journal of hematology.

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.

T. Yau, S. Rutella, J. Dipersio, 2020, Blood advances.

Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease

Xiwei Wu, I. Aldoss, A. Salhotra, 2022, Bone Marrow Transplantation.

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

I. Aldoss, J. Longmate, D. Diamond, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

I. Aldoss, J. Longmate, D. Diamond, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.

I. Aldoss, Jeffrey S. Miller, J. Zaia, 2016, The Lancet. Haematology.

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma

P. Bierman, I. Aldoss, S. Blumel, 2009, Cancer management and research.

Cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic hematopoietic stem cell transplantation: viremia, immunogenicity and survival outcomes in a randomised phase 1b trial

I. Aldoss, Jeffrey S. Miller, J. Zaia, 2015, The Lancet. Haematology.

Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus‐specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis

I. Aldoss, D. Diamond, A. Artz, 2023, American journal of hematology.

Post-transplant sinusoidal obstruction syndrome in adult patients with B-cell Acute Lymphoblastic Leukemia treated with pre-transplant Inotuzumab.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia

S. Rutella, J. Dipersio, Catherine Lai, 2020, bioRxiv.

Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

G. Marcucci, I. Aldoss, A. Fathi, 2020 .

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study

J. Dipersio, N. Shukla, I. Aldoss, 2022, Blood.

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens

G. Marcucci, I. Aldoss, S. Forman, 2021, Bone Marrow Transplantation.

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, D. Snyder, 2016, Clinical Lymphoma, Myeloma & Leukemia.

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

S. Rutella, J. Dipersio, M. Jongen‐Lavrencic, 2020 .

A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

A. Nademanee, G. Marcucci, I. Aldoss, 2020 .

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status

D. Weisenburger, G. Marcucci, I. Aldoss, 2017, Haematologica.

Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, V. Pullarkat, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study

G. Marcucci, I. Aldoss, S. Forman, 2023, Frontiers in Immunology.

Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

G. Marcucci, I. Aldoss, S. Forman, 2020 .

Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis

G. Marcucci, I. Aldoss, S. Forman, 2019, Blood.

The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis.

F. Gao, P. Westervelt, J. Dipersio, 2022, Blood.

Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

I. Aldoss, S. Forman, V. Pullarkat, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The feasibility of additional CD19‐targeted cellular therapy in relapsed/refractory B‐ALL with re‐emergence of CD19 antigen after prior CD19‐negative relapse

G. Marcucci, I. Aldoss, S. Forman, 2022, American journal of hematology.

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

R. Larson, K. Mrózek, M. Liedtke, 2022, Blood advances.

Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

I. Aldoss, V. Pullarkat, I. Amanam, 2022, Leukemia & lymphoma.

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Lixin Yang, G. Marcucci, I. Aldoss, 2021, Blood Cancer Journal.

Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data

M. Liedtke, M. Wadleigh, I. Aldoss, 2021, Bone Marrow Transplantation.

Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.

G. Marcucci, I. Aldoss, S. Forman, 2021, Leukemia research.

Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia

M. Liedtke, M. Wadleigh, I. Aldoss, 2020, Cancer.

Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab.

M. Liedtke, M. Wadleigh, I. Aldoss, 2019, Blood advances.

Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.

C. Flowers, M. Perales, A. Viswabandya, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation.

A. Nademanee, G. Marcucci, I. Aldoss, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.

A. Nademanee, I. Aldoss, S. Forman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adjuvant Treatment and Predictors of Response in Colon Cancer

I. Aldoss, S. Iqbal, 2011 .

Outcome disparities in multiple myeloma: a SEER‐based comparative analysis of ethnic subgroups

A. Chanan-Khan, P. Razavi, Dongyun Yang, 2012, British journal of haematology.

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults

I. Aldoss, M. Akhtari, V. Chow, 2016, Therapeutics and clinical risk management.

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.

Samuel W. Brady, C. Pui, T. Haferlach, 2022, Blood.

SWOG 1312 Final Results: A Phase 1 Trial of Inotuzumab in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Relapsed/ Refractory CD22+ Acute Leukemia

M. Liedtke, M. Othus, I. Aldoss, 2019, Blood.

Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia

B. Wood, W. Stock, R. Stone, 2018, Blood.

Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children.

G. Marcucci, I. Aldoss, V. Pullarkat, 2016, Oncology.

Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy

I. Aldoss, V. Pullarkat, M. Afkhami, 2023, Leukemia & lymphoma.

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions

G. Marcucci, I. Aldoss, P. Curtin, 2023, American journal of hematology.

I. Aldoss, S. Forman, V. Pullarkat, 2015, Bone Marrow Transplantation.

Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

B. Ebert, R. Larson, J. Greally, 2022, Blood.

Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.

M. Liedtke, M. Wadleigh, I. Aldoss, 2020, Clinical lymphoma, myeloma & leukemia.

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

I. Aldoss, V. Pullarkat, L. Budde, 2022, Blood advances.

Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia

G. Marcucci, I. Aldoss, S. Forman, 2017, American journal of hematology.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

S. Armstrong, J. Dipersio, N. Shukla, 2023, Nature.

Effect of Surgical Intervention on Survival of Patients With Clinical N2 Non–Small Cell Lung Cancer: A Veterans’ Affairs Central Cancer Registry (VACCR) Database Analysis

A. Kessinger, I. Aldoss, A. Ganti, 2016, American journal of clinical oncology.

A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL)

J. Dipersio, I. Aldoss, F. Locke, 2021, Blood.

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

A. Nademanee, G. Marcucci, I. Aldoss, 2018, Blood.

Tocilizumab for Cytokine Release Syndrome Management after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

D. Neuberg, T. Graubert, U. Borate, 2022, Blood.

Chilaiditi Syndrome Complicated by Cecal Perforation

I. Aldoss, M. Nusair, Jamil Y. Abuzetun, 2009, Southern medical journal.

Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer — A Veterans Affairs Cancer Registry analysis ☆

I. Aldoss, T. Tashi, A. Ganti, 2011 .

Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias

G. Marcucci, I. Aldoss, A. Salhotra, 2021, Blood.

The Combination of Fludarabine, Cytarabine and Etoposide Is an Active and Well-Tolerated Regimen in Relapsed/Refractory Acute Myeloid Leukemia

Lingyun Ji, I. Aldoss, V. Pullarkat, 2013, Acta Haematologica.

High-Grade Pegylated Asparaginase-Related Hepatotoxicity Occurrence In a Pediatric-Inspired Adult Acute Lymphoblastic Leukemia Regimen Does Not Necessarily Predict Recurrent Hepatotoxicity In Subsequent Cycles

M. Tallman, I. Aldoss, M. Lunning, 2013 .

More opportunities to advance paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia.

I. Aldoss, Lindsey R. Murphy, 2023, The Lancet. Haematology.

The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia

I. Aldoss, S. Forman, V. Pullarkat, 2022, Leukemia & lymphoma.

Genitourinary small cell carcinoma: Analysis of clinical and treatment factors associated with survival among patients in the Veterans Affairs Health System.

I. Aldoss, T. Tashi, S. Subbiah, 2010 .

A retrospective analysis of the impact of antithrombin III supplementation on the incidence of pegaspargase-induced venous thromboembolism.

I. Aldoss, V. Pullarkat, S. Shayani, 2018 .

Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R/R BCP acute lymphoblastic leukemia: a review

I. Aldoss, N. Boissel, B. Shah, 2023, Leukemia & lymphoma.

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

G. Marcucci, I. Aldoss, S. Forman, 2022, Blood.

High prevalence and inferior long‐term outcomes for TP53 mutations in therapy‐related acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, P. Curtin, 2022, American journal of hematology.

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

I. Aldoss, V. Pullarkat, Vaibhav Agrawal, 2023, Frontiers in oncology.

Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia

I. Aldoss, V. Pullarkat, Vaibhav Agrawal, 2023, European journal of haematology.

How I Treat: Selecting CD19 Targeted Immunotherapies in Adult Patients with Advanced Acute Lymphoblastic Leukemia.

I. Aldoss, S. Forman, 2020, Blood.

Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults

Chunxu Qu, C. Mullighan, G. Marcucci, 2018, Blood.

Extramedullary relapse of KMT2A(MLL)-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab.

I. Aldoss, J. Song, 2018, Blood.

Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.

I. Aldoss, L. Muffly, B. Shah, 2023, Journal of Clinical Oncology.

Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T Cell Therapy in Adults with high-risk Relapsed/Refractory ALL.

G. Marcucci, Xiuli Wang, I. Aldoss, 2022, Clinical Cancer Research.

Seliciclib in malignancies

I. Aldoss, T. Tashi, A. Ganti, 2009, Expert opinion on investigational drugs.

A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia

K. Flatten, A. Adjei, I. Aldoss, 2023, Cancer medicine.

Adult Burkitt lymphoma: advances in diagnosis and treatment.

W. Chan, D. Weisenburger, J. Armitage, 2008, Oncology.

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma

P. Bierman, I. Aldoss, S. Blumel, 2009 .

Cancer Management and Research Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress the Role of Bendamustine in the Treatment of Indolent Non-hodgkin Lymphoma

P. Bierman, I. Aldoss, S. Blumel, 2022 .

First report of PhALLCON: A phase 3 study comparing ponatinib (pon) vs imatinib (im) in newly diagnosed patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

H. Kantarjian, E. Jabbour, I. Aldoss, 2023, Journal of Clinical Oncology.

Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate

E. Jabbour, I. Aldoss, S. Fleming, 2022, Blood.

Leveraging CD19CAR T cells early in the treatment of older patients with B-ALL: are we there yet?

I. Aldoss, Mary C. Clark, Xiuli Wang, 2024, Leukemia & lymphoma.

B. Sandmaier, M. Aljurf, M. Grunwald, 2019, Haematologica.

Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.

M. Norkin, R. Vij, W. Wood, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.

H. Kantarjian, I. Aldoss, C. Gambacorti-Passerini, 2024, JAMA.

Minimal Residual Disease-Negative Complete Remission at the End of Induction Is a Prognostic Indicator of Long-Term Survival in Adult Patients with Ph+ Acute Lymphoblastic Leukemia Receiving First-Line Therapy

H. Dombret, H. Kantarjian, E. Jabbour, 2023, Blood.

Blinatumomab improves outcomes for pediatric patients with low-risk B-cell acute lymphoblastic leukemia in first marrow relapse

I. Aldoss, Lindsey Murphy, 2023, Translational Pediatrics.

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

E. Jabbour, I. Aldoss, C. Récher, 2023, Blood.

Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

J. Dipersio, N. Shukla, E. Traer, 2023, Blood.

Toxicity profile of repeated doses of PEG‐asparaginase incorporated into a pediatric‐type regimen for adult acute lymphoblastic leukemia

I. Aldoss, D. Douer, V. Pullarkat, 2016, European journal of haematology.

Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia

I. Aldoss, K. Jacobs, S. Forman, 2023, Haematologica.

Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.

I. Aldoss, A. Salhotra, V. Pullarkat, 2024, Transplantation and cellular therapy.

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia

Xiuli Wang, I. Aldoss, S. Forman, 2023, Blood cancer journal.

Important Considerations in the Intensive Care Management of Acute Leukemias

I. Aldoss, Hoda Pourhassan, Waasil Kareem, 2023, Journal of intensive care medicine.

Glucocorticoid Therapy in Acute Lymphoblastic Leukemia: Navigating Short-Term and Long-Term Effects and Optimal Regimen Selection

I. Aldoss, Hoda Pourhassan, Lindsey Murphy, 2024, Current hematologic malignancy reports.

Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.

I. Aldoss, V. Pullarkat, A. Herrera, 2024, Leukemia & lymphoma.